• Industries
    • Chemicals
    • Cosmetic & Consumer Products
    • Pharmaceuticals & Medical Devices
    • Biocides
  • Services
    • Chemical and Product Safety
    • Regulatory Strategy and Compliance
    • QSAR Modelling
    • New Approach Methodologies
    • Endocrine disruption
    • Product Stewardship
    • Environmental Risk Assessment of Medicinal Products
  • Team
    • Team
    • Collaborations
  • Insights
    • Insights
    • Cases
    • Publications
  • Careers
  • Contact
  • Industries
    • Chemicals
    • Cosmetic & Consumer Products
    • Pharmaceuticals & Medical Devices
    • Biocides
  • Services
    • Chemical and Product Safety
    • Regulatory Strategy and Compliance
    • QSAR Modelling
    • New Approach Methodologies
    • Endocrine disruption
    • Product Stewardship
    • Environmental Risk Assessment of Medicinal Products
  • Team
    • Team
    • Collaborations
  • Insights
    • Insights
    • Cases
    • Publications
  • Careers
  • Contact
  • You are here:
  • Home
  • Insights
  • Assessing cosmetic ingredients for endocrine disrupting properties

Assessing cosmetic ingredients for endocrine disrupting properties

In the EU Cosmetics Regulation, there are no specific provisions addressing endocrine disruptors (ED) but a fitness check conducted by the European Commission (COM(2018)739) concluded that the tools foreseen in the Regulation are suitable to deal with potential health hazards connected with ED. In 2014, the EU Scientific Committee on Consumer Safety (SCCS) adopted a memorandum explaining the assessment process for potential ED. It also specified that the substances should be treated like other substances of concern for human health, therefore, be subject to risk assessment.

The objective of the poster is to present a stepwise ED assessment approach which considers the information derived from New Approach Methodologies (e.g., (Q)SAR, read across and in vitro assays). This approach is in line with the principles laid down in the OECD Conceptual Framework for the testing and assessment of endocrine disruptors and in the ECHA/EFSA 2018 guidance for the identification of EDs under the EU Biocides and Pesticides Regulation.

READ MORE ON THE PDF

More insights

Author
  • Ms. Sanghamitra Mishra

    Ms. Sanghamitra Mishra

  • Dr. Ankushreddy Patil

    Dr. Ankushreddy Patil

  • Dr. Francesca Tencalla

    Dr. Francesca Tencalla

  • Dr. Thomas Petry

    Dr. Thomas Petry

EFSA/ECHA (2018) guidance for the identification of endocrine disruptors (ED): looking back after the first 3 years of implementation

Previous thumb

Safety And Risk Assessment Of Peptides In Cosmetic Products

Next thumb
Scroll

 

ToxMinds are specialised in ensuring product safety and compliance.

We are passionate about toxicology and how emerging scientific developments can be utilised to support our customers in bringing safe, regulatory compliant and sustainable products to the marketplace.

 

 

 

 

Belgium
ToxMinds BV
Avenue de Tervueren 188A, bte 12
B-1150 Brussels Belgium

VAT BE 0877.628.383

Tel: +32 (0)2 762 9145
Email: contact us

 

 

 

 

India
ToxMinds India Consulting Pvt. Ltd.
Unit 305, 3rd Floor, Brigade IRV Centre, Whitefield, Bangalore-560066, India

 

Tel: +91 804 204 19 20
Email: contact us

 

 

 

 

 

LinkedIN
Copyright and disclaimer | Data privacy
  • Home
  • Industries
  • Services
  • Team
  • Insights
  • Careers
  • Contact
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok